BRPI0414803A - derivados de ácido 4-(1-benzofuran-3-il-metilidenoaminoxi-propóxi)-benz óico e compostos relacionados como inibidores de pai-1 para o tratamento de dano do sistema fibrinolìtico e de trombose - Google Patents

derivados de ácido 4-(1-benzofuran-3-il-metilidenoaminoxi-propóxi)-benz óico e compostos relacionados como inibidores de pai-1 para o tratamento de dano do sistema fibrinolìtico e de trombose

Info

Publication number
BRPI0414803A
BRPI0414803A BRPI0414803-7A BRPI0414803A BRPI0414803A BR PI0414803 A BRPI0414803 A BR PI0414803A BR PI0414803 A BRPI0414803 A BR PI0414803A BR PI0414803 A BRPI0414803 A BR PI0414803A
Authority
BR
Brazil
Prior art keywords
aryl
heteroaryl
alkyl
pai
thrombosis
Prior art date
Application number
BRPI0414803-7A
Other languages
English (en)
Inventor
Lisa Marie Havran
John Anthony Butera
Hassan Mahmoud Elokdah
Douglas John Jenkins
Eric Gould Gundersen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0414803A publication Critical patent/BRPI0414803A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

"DERIVADOS DE áCIDO 4-(1-BENZOFURAN-3-IL-METILIDENOAMINOXI-PROPóXI)-BENZ óICO E COMPOSTOS RELACIONADOS COMO INIBIDORES DE PAI-1 PARA O TRATAMENTO DE DANO DO SISTEMA FIBRINOLìTICO E DE TROMBOSE". A presente invenção refere-se a oximas de benzofurila de fórmula (I) ou um sal farmaceuticamente aceitável ou forma de éster deste, em que R~ 1~ é uma ligação direta a A, C~ 1~-C~ 4~ alquileno, ou -O-C~ 1~-C~ 4~ alquileno; R~ 2~ e R~ 3~ são, independentemente, hidrogênio, halogênio, C~ 1~-C~ 4~ alquila, C~ 1~-C~ 3~ perfluoroalquila, -O-C~ 1~-C~ 3~ perfluoroalquila, C~ 1~-C~ 3~ alcóxi, -OH, -NH~ 2~, -NO~ 2~, arila, heteroarila, -O(CH~ 2~)~ p~-arila, -O(CH~ 2~)~ p~-heteroarila, -NH(CH~ 2~)~ p~-arila, -NH(CH~ 2~)~ p~heteroarila, -NH(CO)-arila, -NH(CO)-heteroarila, -O(CO)-arila, -O(CO)heteroarila, -NH(CO)-CH=CH-arila, ou -NH(CO)-CH=CH-heteroarila; p é um número inteiro de 0 a 6; R~ 4~ é hidrogênio, C~ 1~-C~ 8~ alquila, ou C~ 3~-C~ 6~ cicloalquila; A é -COOH ou uma mímica de ácido; X é C~ 1~-C~ 8~ alquileno, C~ 3~-C~ 6~ cicloalquileno, -(CH~ 2~)~ m~O-, ou -(CH~ 2~)~ m~NH-; m é um número inteiro de 1 a 6; e R~ 5~ é hidrogênio, C~ 1~-C~ 8~ alquila, C~ 3~-C~ 6~ cicloalquila, -CH~ 2~-C~ 3~-C~ 6~ cicloalquila, heteroarila, -CH~ 2~-heteroarila, arila, ou benzila; R~ 6~ e R~ 7~, são, independentemente, hidrogênio, halogênio, C~ 1~-C~ 6~ alquila, C~ 1~-C~ 6~ perfluoroalquila, -O-C~ 1~-C~ 6~ perfluoroalquila, C~ 1~-C~ 6~ alcóxi, -OH, -NH~ 2~, -NO~ 2~, -O(CH~ 2~)~ n~-arila, -O(CH~ 2~)~ n~-heteroarila, arila, ou heteroarila; e n é um número inteiro de 0 a 6, onde os grupos de alquila, cicloalquila, arila e heteroarila são cada opcionalmente substituído por um ou mais substituintes. Os presentes compostos são inibidores de PAI-1 para o tratamento por exemplo de enfraquecimento do sistema fibrinolítico, trombose ou doenças cardiovasculares.
BRPI0414803-7A 2003-09-25 2004-09-24 derivados de ácido 4-(1-benzofuran-3-il-metilidenoaminoxi-propóxi)-benz óico e compostos relacionados como inibidores de pai-1 para o tratamento de dano do sistema fibrinolìtico e de trombose BRPI0414803A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50580103P 2003-09-25 2003-09-25
US10/947,930 US20050215626A1 (en) 2003-09-25 2004-09-23 Substituted benzofuran oximes
PCT/US2004/031361 WO2005030199A1 (en) 2003-09-25 2004-09-24 4-(1-benzofuran-3-yl-methylideneaminoxy.propoxy))-benzoic acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairment of the fibrinolytic system and of thrombosis

Publications (1)

Publication Number Publication Date
BRPI0414803A true BRPI0414803A (pt) 2006-11-14

Family

ID=34396267

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414803-7A BRPI0414803A (pt) 2003-09-25 2004-09-24 derivados de ácido 4-(1-benzofuran-3-il-metilidenoaminoxi-propóxi)-benz óico e compostos relacionados como inibidores de pai-1 para o tratamento de dano do sistema fibrinolìtico e de trombose

Country Status (8)

Country Link
US (1) US20050215626A1 (pt)
EP (1) EP1667676A1 (pt)
JP (1) JP2007506758A (pt)
AU (1) AU2004275807A1 (pt)
BR (1) BRPI0414803A (pt)
CA (1) CA2538574A1 (pt)
MX (1) MXPA06003250A (pt)
WO (1) WO2005030199A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2003000253A1 (en) * 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
ATE411288T1 (de) * 2002-12-10 2008-10-15 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
WO2004052855A2 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7348351B2 (en) * 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
CN101044127A (zh) * 2004-08-23 2007-09-26 惠氏公司 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸
BRPI0514544A (pt) * 2004-08-23 2008-06-17 Wyeth Corp ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)
US7186749B2 (en) * 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
JP2009504762A (ja) * 2005-08-17 2009-02-05 ワイス 置換インドール類およびそれらの使用方法
PE20071017A1 (es) * 2006-02-27 2007-11-12 Wyeth Corp Derivados de acido indol sustituido como inhibidores del activador de plasminogeno tipo 1 (pai-1)
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3147276A1 (de) * 1981-11-28 1983-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von indolderivaten, deren verwendung als wertvolle zwischenprodukte und neue 4-hydroxyindole
DE3413363A1 (de) * 1984-04-09 1985-10-17 Merz + Co GmbH & Co, 6000 Frankfurt Benzofuran-2-yl-ethyl-imidazolderivate, verfahren zu ihrer herstellung und pharmazeutische mittel
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
AU4639089A (en) * 1988-12-29 1990-08-01 Ciba-Geigy Ag Methyl esters of aldimino- or ketimino-oxy-ortho-tolylacrylic acid, manufacturing process and fungicides containing them
NZ242290A (en) * 1991-04-15 1994-12-22 Zeneca Ltd Pyridyl and pyrimidinyl substituted oxime-o-benzyl ether derivatives; preparatory processes, fungicidal compositions and an intermediate
DE4213149A1 (de) * 1992-04-22 1993-10-28 Hoechst Ag Akarizide, insektizide und nematizide substituierte (Hetero)-Aryl-Alkyl-ketonoxim-O-ether, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
EP0608862A1 (en) * 1993-01-27 1994-08-03 Lucky Ltd. Novel 6-chloro-2-(4,6-dimethoxypyrimidin-2-yl) oxybenzoic acid ester derivatives, processes for their production an a method for their application as herbicides
US5599663A (en) * 1993-08-27 1997-02-04 Brighan & Women's Hospital Angiotensin IV and analogs as regulators of fibrinolysis
BR9506648A (pt) * 1994-01-27 1997-09-02 Ciba Geigy Ag Processo para a preparação de derivados de éster arilacético via reação de acoplameno cruzada catalisado por paládio
WO1996036615A1 (en) * 1995-05-16 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
ATE239004T1 (de) * 1996-05-20 2003-05-15 Darwin Discovery Ltd Benzofuran carboxamide und ihre therapeutische anwendung
EP1125931A1 (en) * 2000-02-17 2001-08-22 Hunan Research Institute of Chemical Industry Biocidal alkyl-substituted-(hetero)aryl-ketoxime-O-ethers and the production method thereof
WO2001064646A2 (en) * 2000-03-01 2001-09-07 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents

Also Published As

Publication number Publication date
JP2007506758A (ja) 2007-03-22
EP1667676A1 (en) 2006-06-14
CA2538574A1 (en) 2005-04-07
WO2005030199A1 (en) 2005-04-07
MXPA06003250A (es) 2006-06-08
US20050215626A1 (en) 2005-09-29
AU2004275807A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
BRPI0414803A (pt) derivados de ácido 4-(1-benzofuran-3-il-metilidenoaminoxi-propóxi)-benz óico e compostos relacionados como inibidores de pai-1 para o tratamento de dano do sistema fibrinolìtico e de trombose
BRPI0414462A (pt) derivados de ácido 4-(fenil-etilidenoaminóxi-propóxi)-fenil-acético e compostos relacionados como inibidores de pai-1 para o tratamento de dano do sistema fibrinolìtico e de trombose
CO5251463A1 (es) Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos
BRPI0414738A (pt) derivados de ácido acético substituìdos
ATE540021T1 (de) Hydroxansäurederivate als inhibitoren der enzymatischen hdac-aktivität
NO2015020I1 (no) Ceritinib, 5-klor-N-5-metyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oksy]fenyl-N-[2-(propan-2-sulfonyl)fenyl]pyrimidine-2,4-diamin, eller et farmasøytisk akseptabelt salt derav
EA200600509A1 (ru) Соединения пиримидотиофена
Gong et al. Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy
WO2004072047A8 (en) Indoles, benzimidazoles or naphhimidazoles as histone deacetylase (hdac) inhibitors
RS51471B (en) BIPHYNYLOXYXIC ACID DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
KR960701000A (ko) 안트라닐산 유도체(anthranilic acid derivative)
RS51047B (sr) Derivati 4-tetrazolil-4-fenilpiperidina za lečenje bola
WO2011137089A1 (en) Activators of human pyruvate kinase
CA2511214A1 (en) Asthma and allergic inflammation modulators
MA31685B1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
BR0010391A (pt) Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto
WO2009053808A2 (en) Histone deacetylase inhibitors
CA3063111A1 (en) Histone deacetylases (hdacs) inhibitors
MX2008013728A (es) Inductor de neurogenesis o agente terapeutico de neuropatia que abarca el derivado del eter alkilico o sal del mismo.
WO2008076779A3 (en) 2-(piperidin-4-yl0xy)pyrimidin-4-amine derivatives as deoxycytidine kinase inhibitors for the treatment of cancer
MA30311B1 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
PT1590321E (pt) Derivados de arilalquilcarbamatos, sua preparaã†o e sua aplicaã†o em terapia
WO2009028387A1 (ja) プロテアーゼ阻害剤耐性を有する癌の治療薬
DE60130766D1 (de) Serotoninwiederaufnahme-inhibitoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.